계명대학교 의학도서관 Repository

Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization

Metadata Downloads
Author(s)
Duk-Woo ParkYoung-Hak KimSung-Cheol YunSoo-Jin KangSeung-Whan LeeCheol-Whan LeeSeong-Wook ParkIn-Whan SeongJae-Hwan LeeSeung-Jea TahkMyung-Ho JeongYangsoo JangSang-Sig CheongJoo-Young YangDo-Sun LimKi-Bae SeungJei-Keon ChaeSeung-Ho HurSang-Gon LeeJunghan YoonNae-Hee LeeYoung-Jin ChoiHyun-Sook KimKee-Sik KimHyo-Soo KimTaeg-Jong HongHun-Sik ParkSeung-Jung Park
Keimyung Author(s)
Hur, Seung HoKim, Kee Sik
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of the American College of Cardiology
Issued Date
2010
Volume
56
Issue
15
Keyword
angioplastycoronary diseasestents
Abstract
Objectives The aim of this study was to evaluate the relative efficacy and safety of zotarolimus-eluting stents (ZES) in comparison
with the established and widely used sirolimus- (SES) and paclitaxel-eluting stents (PES) in routine clinical
practice.
Background Whether ZES might provide similar clinical and angiographic outcomes in a broad spectrum of patients compared
with SES or PES is undetermined.
Methods We performed a single-blind, multicenter, prospectively randomized trial to compare ZES with SES and PES in
2,645 patients undergoing percutaneous coronary intervention. The primary end point was a composite of major
adverse cardiac events (MACE) (death, myocardial infarction, and ischemia-driven target vessel revascularization)
at 12 months. A noninferiority comparison (ZES vs. SES) and a superiority comparison (ZES vs. PES) were
performed for the primary end point.
Results Baseline clinical and angiographic characteristics were similar in the 3 groups. At 12 months, the ZES group
showed noninferior rates of MACE compared with the SES group (10.2% vs. 8.3%, p for noninferiority = 0.01,
p for superiority = 0.17) and significantly fewer MACE than the PES group (10.2% vs. 14.1%, p for superiority
0.01). The incidence of death or myocardial infarction was similar among the groups (ZES vs. SES vs. PES, 5.8%
vs. 6.9% vs. 7.6%, respectively, p = 0.31). The incidence of stent thrombosis was significantly lower in the SES
group (ZES vs. SES vs. PES, 0.7% vs. 0% vs. 0.8%, respectively, p = 0.02).
Conclusions In this large-scale, practical randomized trial, the use of ZES resulted in similar rates of MACE compared with SES and
in fewer MACE compared with PES at 12 months.
Keimyung Author(s)(Kor)
허승호
김기식
Publisher
School of Medicine
Citation
Duk-Woo Park et al. (2010). Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization. Journal of the American College of Cardiology, 56(15), 1187–1195. doi: 10.1016/j.jacc.2010.03.086
Type
Article
ISSN
0735-1097
DOI
10.1016/j.jacc.2010.03.086
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33720
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.